Novartis AG Receives Buy Rating and CHF120 Price Target from Deutsche Bank.

Deutsche Bank has reaffirmed its Buy rating on Novartis AG with a price target of CHF120.00. The company's shares opened today at CHF101.70. According to TipRanks, Deutsche Bank analyst Emmanuel Papadakis has a 3.7% average return and a 53.06% success rate on recommended stocks. Novartis AG reported a quarterly revenue of CHF14.84 billion and a net profit of CHF4.04 billion for the quarter ending June 30.

Deutsche Bank has reaffirmed its Buy rating on Novartis AG (NVS), setting a price target of CHF120.00. The company's shares opened today at CHF101.70. Analyst Emmanuel Papadakis, a 4-star analyst with a 3.7% average return and a 53.06% success rate on recommended stocks, issued the rating [3]. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and GlaxoSmithKline.

Novartis AG reported a quarterly revenue of CHF14.84 billion and a net profit of CHF4.04 billion for the quarter ending June 30. The company's analyst consensus stands at a Moderate Buy with a price target consensus of CHF102.08, representing a 1.43% upside [1]. In a separate report, UBS analyst Matthew Weston maintained a Hold rating on Novartis AG with a CHF95.00 price target, while J.P. Morgan also maintained a Hold rating with a CHF95.00 price target [1].

The reaffirmation of the Buy rating by Deutsche Bank comes amid positive developments for Novartis AG. The company has successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for adults with heterozygous familial hypercholesterolemia (HeFH). This genetic condition significantly increases the risk of early cardiovascular events such as heart attacks and strokes. The agreement marks an important milestone in expanding treatment options for patients who face a higher risk of early heart disease [2].

While the milestone is significant, public reimbursement through provincial and territorial formularies has not yet been secured. As the next step, Novartis will collaborate with public drug programs to ensure timely access to treatment for eligible patients living with HeFH.

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/NVS/pressreleases/34413521/novartis-ag-novn-receives-a-hold-from-ubs/
[2] https://www.ainvest.com/news/novartis-ag-maintains-buy-rating-deutsche-bank-2508/
[3] https://uk.marketscreener.com/news/novartis-ag-deutsche-bank-reiterates-its-buy-rating-ce7c50dedb8ff72d